Contingent consideration fair value adjustments
Incyte Contingent consideration fair value adjustments increased by 99.4% to -$168.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 101.5%, from $11.57M to -$168.00K. Over 3 years (FY 2021 to FY 2025), Contingent consideration fair value adjustments shows a downward trend with a -25.4% CAGR.
Analysis
How to read this metric
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
Detailed definition
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Peer comparison
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
operating_business_combination_contingent_consideration__7f0be7Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.63M | $2.91M | $1.67M | $6.38M | $3.31M | -$21.89M | $24.35M | $6.20M | $8.37M | -$426.00K | $15.06M | -$456.00K | $893.00K | $23.41M | $11.57M | $22.76M | -$12.20M | -$28.26M | -$168.00K |
| QoQ Change | — | -37.2% | -42.5% | +281.5% | -48.1% | -760.8% | +211.2% | -74.6% | +35.2% | -105.1% | >999% | -103.0% | +295.8% | >999% | -50.6% | +96.7% | -153.6% | -131.5% | +99.4% |
| YoY Change | — | — | — | — | -28.5% | -852.3% | >999% | -2.9% | +152.8% | +98.1% | -38.2% | -107.4% | -89.3% | >999% | >999% | >999% | -152.1% | — | -101.5% |
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $11.57M | $22.76M | -$12.20M | -$28.26M | -$168.00K |
| Total | $11.57M | $22.76M | -$12.20M | -$28.26M | -$168.00K |
Contingent consideration fair value adjustments at Other Companies
Frequently Asked Questions
- What is Incyte's contingent consideration fair value adjustments?
- Incyte (INCY) reported contingent consideration fair value adjustments of -$168.00K in Q1 2026.
- How has Incyte's contingent consideration fair value adjustments changed year-over-year?
- Incyte's contingent consideration fair value adjustments decreased by 101.5% year-over-year, from $11.57M to -$168.00K.
- What is the long-term trend for Incyte's contingent consideration fair value adjustments?
- Over 3 years (2021 to 2025), Incyte's contingent consideration fair value adjustments has grown at a -25.4% compound annual growth rate (CAGR), from $14.74M to -$6.13M.
- What does contingent consideration fair value adjustments mean?
- Changes in the estimated cost of future payments owed to sellers of acquired companies based on performance milestones.